Paglalarawan

Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim to treat, prevent, or potentially cure diseases, and both approaches have the potential to alleviate the underlying cause of genetic diseases and acquired diseases. The global cell and gene therapy market is set to increase by US$ 14.75 billion from 2022 sa 2028, representing a compound annual growth rate (CAGR) ng mga 29.1% sa panahon ng pagtataya.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2018-2021 at forecast na 2028 covering key market aspects like sales value for cell and gene therapy. The global cell and gene therapy market is segmented on the basis of therapy type, produkto, application, and region. On the basis of therapy type, the global cell and gene therapy market has been segmented into gene therapy, cell therapy, at iba pa. Ayon sa produkto, the global cell and gene therapy market has been segmented into Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, at iba pa. Based on application, the global cell and gene therapy market is categorized into rare diseases, oncology, hematology, ophthalmology, neurology, at iba pa. In terms of geography, the global cell and gene therapy market has been segmented into North America, Asya Pasipiko, Europa, Middle East and Africa, and Latin America.

The global cell and gene therapy market is highly competitive. As of 2021, the major players in the global cell and gene therapy market were Amgen Inc., bluebird bio Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Novartis International AG, Orchard Therapeutics plc, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics Inc., Vericel Corporation.

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the cell and gene therapy market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Therapy type: gene therapy, cell therapy, at iba pa
Produkto: Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, at iba pa
Paglalapat: rare diseases, oncology, hematology, ophthalmology, neurology, at iba pa
Rehiyon: Hilagang Amerika, Asya Pasipiko, Europa, Middle East and Africa, and Latin America
Taon na itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2018 sa 2028

Mga Pangunahing Benepisyo para sa mga Stakeholder

– Get a comprehensive picture of the global cell and gene therapy market
– Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan

Talaan ng mga Nilalaman

1. Kahulugan ng merkado
2. Paraan ng pananaliksik
3. Data ng merkado at pananaw
3.1 Mga pagtatantya sa laki ng merkado
3.2 Pagtataya ng Pagtataya
4. Cell and gene therapy market by therapy type
4.1 Gene therapy
4.2 Cell therapy
4.3 Ang iba naman
5. Cell and gene therapy market by product
5.1 Zolgensma
5.2 Yescarta
5.3 Kymriah
5.4 Zynteglo
5.5 Maci
5.6 Tecartus
5.7 Ang iba naman
6. Cell and gene therapy market by application
6.1 Rare diseases
6.2 Oncology
6.3 Hematology
6.4 Ophthalmology
6.5 Neurology
6.6 Ang iba naman
7. Cell and gene therapy market by region
7.1 Hilagang Amerika
7.2 Asya Pasipiko
7.3 Europa
7.4 Middle East and Africa
7.5 Latin America
8. Mga profile ng kumpanya
8.1 Amgen Inc.
8.2 bluebird bio, Inc.
8.3 Dendreon Pharmaceuticals LLC
8.4 Gilead Sciences, Inc.
8.5 Novartis International AG
8.6 Orchard Therapeutics plc
8.7 Shenzhen SiBiono GeneTech Co., Ltd.
8.8 Spark Therapeutics, Inc.
8.9 Vericel Corporation
9. Apendiks
9.1 Tungkol sa StrategyHelix
9.2 Pagtanggi